Downregulation of quinone reductase 2 attenuates vascular smooth muscle cells proliferation and neointimal formation in balloon injured rat carotid artery

Cellular Physiology and Biochemistry

Volumn 29, Issue 3-4, 2012, Pages 453-462

  Zhang, Xi Wen ^a,b   Wang, Yao ^b   Cai, Jing Bo ^c   Hou, Xiao Feng ^b   Wang, He Gui ^b   Zou, Jian Gang ^b   Cao, Ke Jiang ^b  

^a THE AFFILIATED HUAIAN NO 1 PEOPLE S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c Jiangsu Province Geriatric Hospital   (China)

Author keywords

Gene therapy; Lentiviral vectors; Neointimal formation; Quinone reductase 2; Vascular smooth muscle cells

Indexed keywords

FLAVOPROTEIN; LENTIVIRUS VECTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; QUINONE REDUCTASE 2; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CAROTID ARTERY INJURY; CELL PROLIFERATION; COMMON CAROTID ARTERY; DOWN REGULATION; ENZYME PHOSPHORYLATION; GENE TRANSFER; IMMUNOHISTOCHEMISTRY; MALE; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

RATTUS;

EID: 84859893407     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000338499     Document Type: Article

References (39)

1. Grüntzig AR, Senning A, Siegenthaler WE: Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979;301:61-68. (Pubitemid 9229695)
2. Kobayashi J: Current status of coronary artery bypass grafting. Gen Thorac Cardiovasc Surg 2008;56:260-267. (Pubitemid 351873707)
3. Brophy JM, Belisle P, Joseph L: Evidence for use of coronary stents: A hierarchical bayesian meta-analysis. Ann Intern Med 2003;138:777-786.
4. Simons M, Edelman ER, DeKeyser JL, Langer R, Rosenberg RD: Antisense cmyb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 1992;359:67-70.
5. Bennett MR, O'Sullivan M: Mechanisms Implications for design of rational therapy of angioplasty and stent restenosis. Pharmacol Ther 2001;91:149-166. (Pubitemid 33139799)
6. Hao H, Gabbiani G, Bochaton-Piallat ML: Arterial smooth muscle cell heterogeneity: implications for atherosclerosis and restenosis development. Arterioscler Thromb Vasc Biol 2003;23:1510-1520. (Pubitemid 37108191)
7. Ishizawa K, Izawa-Ishizawa Y, Ohnishi S, Motobayashi Y, Kawazoe K, Hamano S, Tsuchiya K, Tomita S, Minakuchi K, Tamaki T: Quercetin glucuronide inhibits cell migration and proliferation by platelet-derived growth factor in vascular smooth muscle cells. J Pharmacol Sci 2009;109:257-264.
8. Ekshyyan VP, Hebert VY, Khandelwal A, Dugas TR: Resveratrol inhibits rat aortic vascular smooth muscle cell proliferation via estrogen receptor dependent nitric oxide production. J Cardiovasc Pharmacol 2007;50:83-93. (Pubitemid 47220451)
9. Kim TJ, Zhang YH, Kim Y, Lee CK, Lee MK, Hong JT, Yun YP: Effects of apigenin on the serum- and platelet derived growth factor-BB-induced proliferation of rat aortic vascular smooth muscle cells. Planta Med 2002;68:605-609. (Pubitemid 34827925)
10. Huang HC, Lai MW, Wang HR, Chung YL, Hsieh LM, Chen CC: Antiproliferative effect of esculetin on vascular smooth muscle cells: possible roles of signal transduction pathways. Eur J Pharmacol 1993;237:39-44.
11. Wang Z, Hsieh TC, Zhang Z, Ma Y, Wu JM: Identification and purification of resveratrol targeting proteins using immobilized resveratrol affinity chromatography. Biochem Biophys Res Commun 2004;323:743-749. (Pubitemid 39243382)
12. Buryanovskyy L, Fu Y, Boyd M, Ma Y, Hsieh TC, Wu JM, Zhang Z: Crystal structure of quinone reductase 2 in complex with resveratrol. Biochemistry 2004;43:11417-11426. (Pubitemid 39186963)
13. Long DJ, Jaiswal AK: NRH: Quinone oxidoreductase2 (NQO2). Chem Biol Interact 2000;129:99-112.
14. Cai JB, Zhang ZH, Xu DJ, Qian ZY, Wang ZR, Huang YZ, Zou JG, Cao KJ: Negative regulation of quinone reductase 2 by resveratrol in cultured vascular smooth muscle cells. Clin Exp Pharmacol Physiol 2008;35:1419-1425.
15. Yoo AR, Koh SH, Cho GW, Kim SH: Inhibitory effects of cilostazol on proliferation of vascular smooth muscle cells (VSMCs) through suppression of the ERK1/2 pathway. J Atheroscler Thromb 2010;17:1009-1018.
16. Lee B, Lee EJ, Kim DI, Park SK, Kim WJ, Moon SK: Inhibition of proliferation and migration by piceatannol in vascular smooth muscle cells. Toxicol In Vitro 2009;23:1284-1291.
17. Griendling KK, Sorescu D, Ushio-Fukai M: NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000;86:494-501. (Pubitemid 30165039)
18. Choi KW, Park HJ, Jung DH, Kim TW, Park YM, Kim BO, Sohn EH, Moon EY, Um SH, Rhee DK, Pyo S: Inhibition of TNF-á-induced adhesion molecule expression by diosgenin in mouse vascular smooth muscle cells via downregulation of the MAPK, Akt and NF-êB signaling pathways. Vascul Pharmacol 2010;53:273-280.
19. Satoh K, Nigro P, Matoba T, O'Dell MR, Cui Z, Shi X, Mohan A, Yan C, Abe J, Illig KA, Berk BC: Cyclophilin A enhances vascular oxidative stress and the development of angiotensin IIinduced aortic aneurysms. Nat Med 2009;15:649-656.
20. Wu JR, Liou SF, Lin SW, Chai CY, Dai ZK, Liang JC, Chen IJ, Yeh JL: Lercanidipine inhibits vascular smooth muscle cell proliferation and neointimal formation via reducing intracellular reactive oxygen species and inactivating Ras-ERK1/2 signaling. Pharmacol Res 2009;59:48-56.
21. Indolfi C, Esposito G, Di Lorenzo E, Rapacciuolo A, Feliciello A, Porcellini A, Avvedimento VE, Condorelli M, Chiariello M: Smooth muscle cell proliferation is proportional to the degree of balloon injury in a rat model of angioplasty. Circulation 1995;92:1230-1235.
22. Zou J, Huang Y, Cao K, Yang G, Yin H, Len J, Hsieh TC, Wu JM: Effect of resveratrol on intimal hyperplasia after endothelial denudation in an experimental rabbit model. Life Sci 2000;68:153-163.
23. Kearney M, Pieczek A, Haley L, Losordo DW, Andres V, Schainfeld R, Rosenfield K, Isner JM: Histopathology of in-stent restenosis in patients with peripheral artery disease. Circulation 1997;95:1998-2002. (Pubitemid 27184264)
24. You XM, Mungrue IN, Kalair W, Afroze T, Ravi B, Sadi AM, Gros R, Husain M: Conditional expression of a dominantnegative c-Myb in vascular smooth muscle cells inhibits arterial remodeling after injury. Circ Res 2003;92:314-321. (Pubitemid 36258554)
25. Sousa JE, Serruys PW, Costa MA: New frontiers in cardiology: drug-eluting stents: Part I. Circulation 2003;107:2274-2279. (Pubitemid 36547225)
26. Daemen J, Serruys PW: Drug-eluting stent update 2007: part I. A survey of current and future generation drug-eluting stents: meaningful advances or more of the same? Circulation 2007;116:316-328. (Pubitemid 47196568)
27. Levonen AL, Vähäkangas E, Koponen JK, Ylä-Herttuala S: Antioxidant gene therapy for cardiovascular disease: current status and future perspectives. Circulation 2008;117:2142-2150. (Pubitemid 351572172)
28. Yang J, Jiang H, Chen SS, Chen J, Li WQ, Xu SK, Wang JC: Lentivirus-mediated RNAi targeting CREB binding protein attenuates neointimal formation and promotes re-endothelialization in balloon injured rat carotid artery. Cell Physiol Biochem 2010;26:441-448.
29. Kawase Y, Ladage D, Hajjar RJ: Method of gene delivery in large animal models of cardiovascular diseases. Methods Mol Biol 2011;709:355-367.
30. Griendling KK, FitzGerald GA: Oxidative Stress and Cardiovascular Injury Part I: Basic Mechanisms and In Vivo Monitoring of ROS. Circulation 2003;108:1912-1916. (Pubitemid 37296532)
31. Zalba G, Beaumont J, San José G, Fortuño A, Fortuño MA, Díez J: Vascular oxidant stress: molecular mechanisms and pathophysiological implications. J Physiol Biochem 2000; 56:57-64.
32. Vella F, Ferry G, Delagrange P, Boutin JA: NRH:quinone reductase 2: an enzyme of surprises and mysteries. Biochem Pharmacol 2005;71:1-12. (Pubitemid 41715231)
33. Gong X, Gutala R, Jaiswal AK: Quinone oxidoreductases and vitamin K metabolism. Vitam Horm 2008;78:85-101.
34. Long DJ 2nd, Iskander K, Gaikwad A, Arin M, Roop DR, Knox R, Barrios R, Jaiswal AK: Disruption of dihydronicotinamide riboside:quinine oxidoreductase 2 (NQO2) leads to myeloid hyperplasia of bone marrow and decreased sensitivity to menadione toxicity. J Biol Chem 2002;277:46131-46139. (Pubitemid 35417602)
35. Won SM, Park YH, Kim HJ, Park KM, Lee WJ: Catechins inhibit angiotensin II-induced vascular smooth muscle cell proliferation via mitogen-activated protein kinase pathway. Exp Mol Med 2006;38:525-534.
36. El-Mowafy AM, Alkhalaf M, Nassar NN: Resveratrol reverses ET-1-evoked mitogenic effects in human coronary arterial cells by activating the kinase-G to inhibit ERK-enzymes. Int J Cardiol 2009;136:263-269.
37. Ahn KS, Gong X, Sethi G, Chaturvedi MM, Jaiswal AK, Aggarwal BB: Deficiency of NRH: quinine oxidoreductase 2 differentially regulates TNF signaling in keratinocytes: upregulation of apoptosis correlates with downregulation of cell survival kinases. Cancer Res 2007;67:10004-10011. (Pubitemid 47621251)
38. Hiltunen MO, Turunen MP, Laitinen M, Ylä-Herttuala S: Insights into the molecular pathogenesis of atherosclerosis and therapeutic strategies using gene transfer. Vasc Med. 2000;5:41-48. (Pubitemid 30143361)
39. Laitinen M, Ylä-Herttuala S: Adventitial gene transfer to arterial wall. Pharmacol Res 1998;37:251-254. (Pubitemid 28230418)